Status:
COMPLETED
Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Non Small Cell Lung Cancer (NSCLC)
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
This study compared two doses of pembrolizumab (MK-3475) versus docetaxel in participants with non-small cell lung cancer (NSCLC) who had experienced disease progression after platinum-containing syst...
Eligibility Criteria
Inclusion
- Life expectancy of at least 3 months
- Histologically- or cytologically-confirmed diagnosis of NSCLC that is anti-programmed cell death ligand 1 (PD-L1) positive per central laboratory review
- At least one bi-dimensional measurable lesion
- Radiographic progression after treatment with at least 2 cycles of a platinum-containing doublet
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
Exclusion
- Prior therapy with docetaxel for NSCLC
- Receiving systemic steroid therapy within 3 days prior to the first dose of study treatment or receiving any other form of immunosuppressive medication
- Currently participating or has participated in a study using an investigational antineoplastic agent or device within 30 days of first dose
- Expected to require any other form of systemic or localized antineoplastic therapy while on trial
- History of allogeneic tissue/solid organ transplant
- Prior systemic cytotoxic chemotherapy, antineoplastic biological therapy (e.g., cetuximab), major surgery within 3 weeks of the first dose of study drug; received thoracic radiation therapy of \>30 Gy within 6 months of the first dose of study drug; received prior tyrosine kinase inhibitor therapy or completed palliative radiotherapy within 7 days of the first dose of study drug
- Prior therapy with an anti-programmed cell death (PD)-1, anti-PD-L1, anti-PD-L2, anti-tumor necrosis factor CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways), or took part in another pembrolizumab trial
- Known history of prior malignancy, with the exception of basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, or in situ cervical cancer, and has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy
- Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
- Active autoimmune disease, or a documented history of autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents
- Interstitial lung disease, or history of pneumonitis requiring systemic steroids for treatment
- Known history or active human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
- Pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial through 120 days after last dose of pembrolizumab or 180 days after last dose of docetaxel
Key Trial Info
Start Date :
August 9 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2020
Estimated Enrollment :
1034 Patients enrolled
Trial Details
Trial ID
NCT01905657
Start Date
August 9 2013
End Date
September 30 2020
Last Update
October 6 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.